Recurrence of focal segmental glomerulosclerosis after kidney transplantation: Strategies and outcome

Current Opinion in Organ Transplantation

Volumn 15, Issue 5, 2010, Pages 628-632

  Ulinski, Tim ^a  

^a ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

immunosuppression; plasma exchange; posttransplant recurrence; rituximab; steroidresistant nephrotic syndrome

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; PODOCIN; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

DRUG MEGADOSE; FOCAL GLOMERULONEPHRITIS; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; GRAFT SURVIVAL; HEREDITY; HETEROZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVING DONOR; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PLASMAPHERESIS; PROTEINURIA; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR;

ADOLESCENT; AGE FACTORS; CHILD; GENETIC PREDISPOSITION TO DISEASE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; NEPHROTIC SYNDROME; PLASMA EXCHANGE; PROTEINURIA; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957600499     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833dee3a     Document Type: Review

References (47)

1. Hoyer JR, Vernier RL, Najarian J.S., et al. Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet 1972; 2: 343-348.
2. Zimmerman SW. Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 1984; 22: 32-38.
3. Lagrue G, Branellec A, Niaudet P., et al. Transmission of nephrotic syndrome to two neonates: spontaneous regression. Presse Med 1991; 20: 255-257.
4. Dantal J, Bigot E, Bogers W., et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330: 7-14.
5. Cochat P, Fargue S, Mestrallet G., et al. Disease recurrence in paediatric renal transplantation. Pediatr Nephrol 2009; 24: 2097-2108.
6. Cochat P. Is there a need for a multicenter study to determine the optimal approach to recurrent nephrotic syndrome following renal transplantation? Pediatr Transplant 2001; 5: 394-397.
7. Ichikawa I, Fogo A. Focal segmental glomerulosclerosis. Pediatr Nephrol 1996; 10: 374-391.
8. Vincenti F, Ghiggeri GM New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 2005; 5: 1179-1185.
9. Senggutuvan P, Cameron JS, Hartley RB, et al. Recurrence offocal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol 1990; 4: 21-28.
10. Weber S, Tonshoff B. Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: clinical and genetic aspects. Transplantation 2005; 80: S128-S134.
11. Nathanson S, Cochat P, Andre J.L., et al. Recurrence of nephrotic syndrome after renal transplantation: influence of increased immunosuppression. Pediatr Nephrol 2005; 20: 1801-1804.
12. Tejani A, Stablein DH Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1992; 2: S258-S263.
13. Broyer M, Selwood N, Brunner F. Recurrence of primary renal disease on kidney graft: an European pediatric experience. J Am Soc Nephrol 1992; 2: S255-S257.
14. Dall'Amico R, Ghiggeri G, Carraro M, et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 1999; 34: 1048-1055.
15. Wuhl E, Fydryk J, Wiesel M., et al. Impact of recurrent nephrotic syndrome after renal transplantation in young patients. Pediatr Nephrol 1998; 12: 529-533.
16. Ingulli E, Tejani A, Butt K.M., et al. High-dose cyclosporine therapy in recurrent nephrotic syndrome following renal transplantation. Transplantation 1990; 49: 219-221.
17. Schachter AD. The pediatric nephrotic syndrome spectrum: clinical homogeneity and molecular heterogeneity. Pediatr Transplant 2004; 8: 344-348.
18. Schachter AD, Harmon WE Single-center analysis of early recurrence of nephrotic syndrome following renal transplantation in children. Pediatr Transplant 2001; 5: 406-409.
19. First MR. Living-related donor transplants should be performed with caution in patients with focal segmental glomerulosclerosis. Pediatr Nephrol 1995; 9 (SUPPL.): S40-S42.
20. Baum MA. Outcomes after renal transplantation for FSGS in children. Pediatr Transplant 2004; 8: 329-333.
21. Winn MP, Alkhunaizi AM, Bennett W.M., et al. Focal segmental glomerulo-sclerosis: a need for caution in live-related renal transplantation. Am J Kidney Dis 1999; 33: 970-974.
22. Ismail-Allouch M., Burke G, Nery J., et al. Rapidly progressive focal segmental glomerulosclerosis occurring in a living related kidney transplant donor: case report and review of 21 cases of kidney transplants for primary FSGS. Transplant Proc 1993; 25: 2176-2177.
23. Boute N, Gribouval O, Roselli S., et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24: 349-354.
24. Karle SM, Uetz B, Ronner V, et al. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13: 388-393.
25. Caridi G, Bertelli R, Di Duca M, et al. Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol 2003; 14: 1278-1286.
26. Weber S, Gribouval O, Esquivel E.L., et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004; 66: 571-579.
27. Bertelli R, Ginevri F, Caridi G., et al. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 2003; 41: 1314-1321.
28. Ruf RG, Lichtenberger A, Karle S.M., et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15: 722-732.
29. Lorton F, Raynot J, Letavernier B., et al. Gross proteinuria post transplant in a child with nephrotic syndrome of the Finnish type - mechanical vs immunological pathogenesis. Nephrol Dial Transplant 2006; 21: 3579-3582.
30. Fujisawa M, Iijima K, Ishimura T., et al. Long-term outcome of focal segmental glomerulosclerosis after Japanese pediatric renal transplantation. Pediatr Nephrol 2002; 17: 165-168.
31. Salomon R, Gagnadoux MF, Niaudet P. Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children. Transplantation 2003; 75: 810-814.
32. Hirano T, Akashi T, Keira T., et al. Clinical impact of cyclosporine cellular pharmacodynamics in minimal change nephrotic syndrome. Clin Pharmacol Ther 2000; 68: 532-540.
33. McCauley J, Shapiro R, Jordan M., et al. FK 506 in the management of nephrotic syndrome after renal transplantation. Transplant Proc 1993; 25: 1351-1354.
34. Cheong HI, Han HW, Park HW, et al. Early recurrent nephrotic syndrome after renal transplantation in children with focal segmental glomerulosclerosis. Nephrol Dial Transplant 2000; 15: 78-81.
35. Meyer TN, Thaiss F, Stahl RA Immunoadsorption and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 2007; 20: 1066-1071.
36. Hristea D, Hadaya K, Marangon N., et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007; 20: 102-105.
37. Nozu K, Iijima K, Fujisawa M., et al. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005; 20: 1660-1663.
38. Gossmann J, Scheuermann EH, Porubsky S, et al. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl Int 2007; 20: 558-562.
39. Nakayama M, Kamei K, Nozu K., et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 2008; 23: 481-485.
40. Bayrakci US, Baskin E, Sakalli H., et al. Rituximab for posttransplant recur- rences of FSGS. Pediatr Transplant 2009; 13: 240-243.
41. Kamar N, Faguer S, Esposito L, et al. Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 2007; 67: 250-254.
42. Hickson LJ, Gera M, Amer H., et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009; 87: 1232-1239.
43. Dello Strologo L., Guzzo I, Laurenzi C., et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 2009; 88: 417-420.
44. Rodriguez-Ferrero M., Ampuero J, Anaya F. Rituximab and chronic plasma- pheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis. Transplant Proc 2009; 41: 2406-2408.
45. Yabu JM, Ho B, Scandling J.D., et al. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 2008; 8: 222-227.
46. Sellier-Leclerc A.L., Macher MA, Loirat C, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2010; 25: 1109-1115.
47. Leroy S, Guigonis V, Bruckner D., et al. Successful anti-TNFalpha treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis. Am J Transplant 2009; 9: 858-861.